Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients

[31] Snyder JJ(2004)A cluster of metabolic defects caused by mutation in a mitochondrial tRNA Science 306 1190-1194

[32] Gilbertson D(2014)Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients Gene 538 195-198

[33] Matas AJ(2013)FK506 affects mitochondrial protein synthesis and oxygen consumption in human cells Cell Biol Toxicol 29 407-414

[34] Hjelmesaeth J(2003)Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria Br J Pharmacol 138 369-376

[35] Sagedal S(1993)Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation Drugs 46 746-794

[36] Hartmann A(1995)FK506 in solid organ transplantation Ther Drug Monit 17 592-595

[37] Rollag H(1995)A prospective randomized trial of FK506-based immunosuppression after renal transplantation Transplantation 59 485-490

[38] Egeland T(1993)Relationship of ionized magnesium and cyclosporine level in renal transplant recipients Ann N Y Acad Sci 696 408-411

[39] Hagen M(2003)Long-term calcineurin inhibition and magnesium balance after renal transplantation Transpl Int 16 76-81

[40] Nordal KP(2006)Tacrolimus-associated hypomagnesemia in renal transplant recipients Transplant Proc 38 1320-1322

[31] Snyder JJ(2004)A cluster of metabolic defects caused by mutation in a mitochondrial tRNA Science 306 1190-1194

[32] Gilbertson D(2014)Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients Gene 538 195-198

[33] Matas AJ(2013)FK506 affects mitochondrial protein synthesis and oxygen consumption in human cells Cell Biol Toxicol 29 407-414

[34] Hjelmesaeth J(2003)Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria Br J Pharmacol 138 369-376

[35] Sagedal S(1993)Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation Drugs 46 746-794

[36] Hartmann A(1995)FK506 in solid organ transplantation Ther Drug Monit 17 592-595

[37] Rollag H(1995)A prospective randomized trial of FK506-based immunosuppression after renal transplantation Transplantation 59 485-490

[38] Egeland T(1993)Relationship of ionized magnesium and cyclosporine level in renal transplant recipients Ann N Y Acad Sci 696 408-411

[39] Hagen M(2003)Long-term calcineurin inhibition and magnesium balance after renal transplantation Transpl Int 16 76-81

[40] Nordal KP(2006)Tacrolimus-associated hypomagnesemia in renal transplant recipients Transplant Proc 38 1320-1322